The HPV Vaccine Race
This article was originally published in RPM Report
GlaxoSmithKline has some catching up to do in the race for what promises to be the world's biggest dollar-volume vaccine market. The company's human papilloma virus vaccine, Cervarix, is a year behind Merck's Gardasil in clinical development. The outcome of the race is by no means a foregone conclusion, however; development strategies, and how the social-conservative card plays out--will decide the winner in the newest vaccine market.
You may also be interested in...
A House hearing on prescription abuse highlighted a potential OTC switch: naloxone for opioid overdose.
Two years after shaking up the vaccine field with its big entry-acquisition of Chiron, Novartis AG has identified a make-or-break pair of projects in the meningitis area. The meningitis vaccines will determine whether the Novartis bet on vaccines will turn into a smart long-term diversification or a low-return move into an unfamiliar and unfriendly segment of health care.
Wyeth's conjugated pneumococcal vaccine continues to break records. The company boldly says there is a lot of growth left, enough to take the product through $3 billion a year and perhaps to $4.5 billion. No vaccine has ever reached those heights. Can Wyeth pull it off?